Kryxana 200mg Tablet

About

Kryxana 200mg Tablet contains Ribociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor. This medication is specifically designed for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Ribociclib works by selectively inhibiting CDK4 and CDK6, which are crucial regulators of cell cycle progression. By blocking these kinases, the drug prevents cancer cells from dividing and growing, thereby slowing down tumor progression.

It is typically used in combination with an aromatase inhibitor as a first-line treatment, or with fulvestrant in subsequent lines of therapy. The targeted action of Ribociclib helps to overcome resistance mechanisms and significantly improves progression-free survival in eligible patients. Due to its specific mechanism of action, regular monitoring for potential side effects, particularly hematological and cardiac, is essential during treatment.

Uses

• HR-positive, HER2-negative advanced breast cancer
• Metastatic breast cancer
• First-line treatment in combination with an aromatase inhibitor
• Second-line treatment in combination with fulvestrant

Directions For Use

Take orally once daily for 21 consecutive days, followed by 7 days off. Take with or without food as directed by your doctor.

Benefits

• Significantly improves progression-free survival
• Delays disease progression effectively
• Highly effective in combination therapy
• Offers convenient oral administration
• Targeted therapy for specific breast cancer types
• Improves overall response rates

Side Effects

• Neutropenia
• Nausea
• Fatigue
• Diarrhea
• Hair thinning
• Vomiting
• Headache
• Rash
• Elevated liver enzymes
• Prolonged QT interval
• Interstitial lung disease
• Thrombocytopenia

Safety Measures

• Alcohol - Avoid or limit alcohol consumption due to potential for increased liver toxicity and other side effects.
• Pregnancy - Contraindicated due to potential fetal harm; effective contraception is required for women of childbearing potential.
• Breastfeeding - Not recommended as Ribociclib may pass into breast milk and potentially harm the infant.
• Liver - Monitor liver function tests closely; dose adjustment or interruption may be needed for severe impairment.
• Kidney - Use with caution; dose adjustment may be required in patients with severe renal impairment.
• Lung - Monitor for signs of interstitial lung disease/pneumonitis; discontinue if severe respiratory symptoms occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.